Morgan Stanley lowered the firm’s price target on GE HealthCare to $74 from $78 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GEHC:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Snap upgraded, Okta downgraded: Wall Street’s top analyst calls
- GE HealthCare initiated with a Hold at Jefferies
- GE HealthCare reports FDA 510K clearance of Critical Care Suite 2.1
- iCAD announces AI solutions to be offered in new MyBreastAI offering